Thank today. you you Giovanni, our joining and thank call all for
discuss with performance growth increased pleased I'm globe. X. medicines across strong our to our our top-line Quarter, Let Slide this driven by the very on start me double-digit demand for key
Slide or teams, robust our the the COVID of strong performance year-over-year, currency. year, experienced our of last color execution well at on Eliquis, half performance commercial Quarter increased additional versus X. products. X% related commercial performance was strong, as most with new XX% as for buying global and which now of the for normalizes was for demand strong launches, demonstrates Looking key This provide excluding up brands first our we up Eliquis both sales This last X% the our starting another I'll year. of patterns on with year,
sales with buying year related the share patterns. which to When growth growth the U.S. as saw the comparison unwinding strong with remained at by overall for of strong In benefited from new-to-brand prescription COVID we this prior total to XX%. prior Quarter driven XX% dynamic, further prescription Second total strong included translate a first growth up year, share expect half favorable for market demand growth. gains, year-over-year continue to looking normalize versus
continue look Third we As further all as and expect Fourth see growing Eliquis continue grow and in Eliquis markets, as we additional OAC class. when a very years. execution demand to dynamics within from strong and share gained had Internationally, geographies, multiple toward the a the with share pleased Quarters, to the room the expect similar of coverage gap number we the to we key very as in previous Overall, grow. we Medicare we one around across world, remain seen reminder, to
start Now me turning let to on very to growth by Slide we're versus saying return to up Quarter, last year. XX% XX, deliver pleased Opdivo this
use strength all 's GI pleased shares upper cancer launch While off leading the 's saw an lung upper we foreign the the first-line and for out approved we're year. our a to across currency growth, the the histologies. will U.S., in the now quarter, core momentum And billed Opdivo Upper well, start. had GI, well, great RCC, in last due renal positive opportunity primarily for XX% launches driven as all, available time. In that year-over-year, in the adjuvant as favorable PD based HERX is the newly both momentum. and was In the outlook Opdivo to growth was first-line and is Opdivo based approximately excluding U.S., cancer. which non-RCC Quarter are CheckMate Opdivo upon XX% on going and potential for of and versus potential few all launches, plus continues The expansion XX%, Opdivo -XXX launches, across -related comparison days, XX% early XX% In in largely sales strong future well benefited COVID were demand sequentially, strong also bladder that brand's recovery XX double-digits as positive COVID another as trials launches of low of to by Outside for new fact dynamics in demand as driven we're on our up performance cancer. important as driven U.S. by this negative contributed clinical muscle-invasive offered current by still from cancers, breadth gastric our from as launched impact our million well GI our well and indications. esophageal, with Cabo last launch PD-X we to year. based future with both with opportunities up lead regimens. do data. seeing esophageal very our with with in very to which with Growth in we impact the months, our start Results a cancer, see a a over first-line Opdivo sales Overall, strong plus Chemo launch, reached therapy All share our gastric indications the renal just and of performance in while including inventory only
nearing Revlimid based therapies, pre-COVID triplet and levels. U.S. to for driven use sales demand treatment by prescriptions we continued multiple our therapies XX%, turning In based encouraged in XX demand in-line was by for Slide global and earlier myeloma Now, up up the Pomalyst portfolio, regarding to primarily lines. increasing strong were driven are globally, see duration. triplet
slide to $XXX continue our Beginning which with an our on sequentially. be generated to in QX, we pleased moving Now very with launches XX, XX% a new Reblozyl, increased recent launches. million
As wind to being growth the continue down, as underlying the MDS by demand launches it's expected. bolus from replaced
sustained their earlier in remain continue year and in half we the receive the treating they expect focused We to growth most patients for sustained ensuring as treatment appropriate on dose benefit. journey second the of new
prescribe Zeposia, SXP and to to in progress where written where MS is of metrics. terms to generated quarter, continues prescriptions, the we which Moving $XX in the Zeposia continue launch to high million choice the see intent of well,
the in have prescriptions time acceleration We seen commercially-supplied also to from an conversion products. written
on Looking Zeposia choice choice, -- see MS. of forward, but SXP the not only focus as of continue for the treatment establishing oral to we we also
early we June. launched in Zeposia colitis in ulcerative and Beyond the MS, U.S.
are in product receptivity encouraged While we the very far. by early so launch, the to physician
plan building on stepwise medicine, differentiator overtime. Our volume while biologic-like establishing is for maximizing demand to process by oral-like this access of focus
well the treatment first growth Onureg, in going only Quarter, double-digit for demonstrated expand with benefit. demand to a physicians Turning as patients, remission FDA the recognizing over Onureg prior to also we with AML approved launch base continue with the user OS is and first
by driven blister our quarter were from cards. bottles by to impacted transition Second inventory, sales reduced
where we sales see in segment, to Remember establish year. maintenance However, treatment. underlying take that a to based second the it Onureg of and upon the demand the treatment expect time trends, will is strength this as the a half shape rebound of new
additional these products encouraged we're we are gaining to driving time. to how through launches and markets going, and Looking at access forward of growth in look reimbursement over these see each internationally,
site our Slide and QX like for has I rapid utilization launch we messages Now, and and cell therapy.Demand differetiated discuss strong. with with execution outpatient sales differentiated CAR-T treaters. are progress, strong cell with activated by two pleased Starting our would with well, driven to among resonating our activation, sites date. more turn million to XX were XX therapy new with high of awareness profile than to Breyanzi, been products XX around
BCMA relates the it in to site very of to sales to advantage leverage of demand accelerate demand. as strong this Next, the Abecma, Quarter, and million onboarding. two our and profile, CAR-T XX the robust led increase to CAR-T footprint hard site over able our for medicines We on looking An differentiated capacity Breyanzi launching of significant first-in-class by at Based seen are product, we have demand time. unmet current simultaneously. we beyond capacity were
both by therapy continue Looking our the see with forward, Abecma demand to seen. franchise, and cell across recent meaningful we've we potential evidenced as long-term Breyanzi and
as about points we the launch turning overall. Now, few a to portfolio think our next slide,
how point million with products cycle. already contributed they are and quarter, launch this each these run Together, the billion rate. encouraged very at we're in of are $XXX $X approaching this progressing have First,
as Importantly, us in future This we these great forward. look diversify and portfolio our to review as we confidence products potential. significant having renew our ability gives
other slide the quarter, on Now, items. few all our we've P&L on focus on sham let line for line you me already XX. I'll through covered a take sales Since a items couple key
First, due last Operating product expenses and higher therapeutic period by primarily our due year, at levels spend pre-launch prior decreased to areas, and investments wave which exchange gross were initial which as than launch across versus foreign normal due time higher mix. that lower were year, were MS&A, is in particularly same to margin offset the than our well of as Remember last foreign the to synergies. COVID. realized exchange, partially year,
driven our EPS primarily Our and effective by significantly topline performance. strong overall primarily year-over-year, XX.X%, mix, non-GAAP tax was by our earnings rate driven increased
capture our XX, with Quarter. billion switching operations the balance billion and strong liquidity capital sheet position cash securities, strong over from Slide our gears $XX and of Now marketable X.X in on the allocation remains to and in
capital allocations priorities remain Our unchanged.
Quarter, and to development. business the portfolio sheet renewing continued we through During the strengthen while balance our diversifying
As both and with two Oncology portfolio Giovanni and Eisai. deals mentioned, we the executed that Agenus diversify Quarter our complement during
continued billion half grade an it in year, tender first $X.X billion debt in As $X reduction, commitment offer, strong the our rating. investment additional maturities demonstrate relates of to to our the
to year and this X billion progresses. As we $X it relates to to $X planned the bought billion as our have billion the share opportunistic already repurchases buyback remain back year, date, will of to
year, and Now, growth are performance, continue our we in to guidance revenue From turning line expect on to full-year non-GAAP perspective, slide following year. XX, for over XXXX this quarter's we reflects significant reaffirming the the bottom growth high-single-digits. last our guidance which a top
we similar that coverage remainder global ' of earlier, phasing terms of year to to the I noted GAAP the for an QX. and Eliquis of In Opdivo inventory due expect unwinding be QX revenues to
the in and sales the of However, encouraged guidance. end our full-year by we higher the strength at are business expect
to for the to assumption margin gross impact the full our product exchange. XX% of year, and foreign updated have mix We primarily due
maintaining expenses, on our Moving R&D low-single-digit of on are full-year of increase increase. guidance we MS&A digit and to mid-single operating
